MAGEA3 and melanoma: We have previously reported the feasability and safety of vaccination with Dex pulsed with MAGE3.A1 and MAGE3.DP04 peptides in 15 HLA-A1/B35+ and DP04+ stage IIIb and IV melanoma patients [42].